Press releaseGlobe Newswire
Relay Therapeutics
RLAY · NASDAQ
$18.45+$1.36 (+7.96%)TodayMarket closed ·
Prev close $17.09
Latest news
- Press releaseGlobe Newswire
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
- Press releasePRNewswire
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
- NewsAvi Kapoor
Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- NewsVandana Singh
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders
- Press releaseGlobe Newswire
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
- Press releaseGlobe Newswire
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
- News
Earnings Scheduled For May 5, 2026
- News
Relay Therapeutics Plans To Move Zovegalisib + Atirmociclib, Pfizer's Investigational, CDK4 Inhibitor, Into Phase 3 Development For Frontline Patients With PI3Kα-Mutated, HR+/HER2- Metastatic Breast Cancer
- Press releaseGlobe Newswire
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
- Press releaseGlobe Newswire
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsVandana Singh
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?
- Press releaseGlobe Newswire
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
- Press releasePRNewswire
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
Relay Therapeutics Q4 Earnings Assessment
- Press releaseGlobe Newswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
- News
Earnings Scheduled For February 26, 2026
- News
Relay Therapeutics Earnings Preview
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
- Press releasePRNewswire
$207B Market Shift: The Race for Fast Track Approval in Oncology
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
- Press releaseGlobe Newswire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
- NewsVandana Singh
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug
- News
Earnings Scheduled For November 6, 2025
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
- Press releaseGlobe Newswire
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
- News
Preview: Relay Therapeutics's Earnings
- Press releasePRNewswire
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
- Press releasePRNewswire
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- NewsAvi Kapoor
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- Press releaseGlobe Newswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- Press releaseGlobe Newswire
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Press releaseGlobe Newswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
- Press releaseGlobe Newswire
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
- Press releaseGlobe Newswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.